{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:56:20Z","timestamp":1781805380258,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40121-026-01353-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:17:28Z","timestamp":1779268648000},"page":"1803-1825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceftaroline for Methicillin-Resistant Staphylococcus aureus Endovascular Infection"],"prefix":"10.1007","volume":"15","author":[{"given":"Reese A.","family":"Cosimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik","family":"Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"10325","key":"1353_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"RC Antimicrobial","year":"2022","unstructured":"Antimicrobial RC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"1353_CR2","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"CDC","year":"2019","unstructured":"CDC. Antibiotic resistance threats in the United States, 2019. Atlanta: U.S. Department of Health and Human Services, CDC; 2019."},{"issue":"1","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","volume":"21","author":"A Hassoun","year":"2017","unstructured":"Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care. 2017;21(1):211. https:\/\/doi.org\/10.1186\/s13054-017-1801-3.","journal-title":"Crit Care"},{"issue":"3","key":"1353_CR4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1353_CR5","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","volume":"48","author":"KL LaPlante","year":"2004","unstructured":"LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48(12):4665\u201372. https:\/\/doi.org\/10.1128\/AAC.48.12.4665-4672.2004.","journal-title":"Antimicrob Agents Chemother"},{"key":"1353_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3410\/M4-4","volume":"4","author":"A Dhand","year":"2012","unstructured":"Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep\u2019): implications for therapy. F1000 Med Rep. 2012;4:4. https:\/\/doi.org\/10.3410\/M4-4.","journal-title":"F1000 Med Rep."},{"issue":"3","key":"1353_CR7","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/s1473-3099(23)00432-2","volume":"24","author":"S Alosaimy","year":"2024","unstructured":"Alosaimy S, Rybak MJ, Sakoulas G. Understanding vancomycin nephrotoxicity augmented by \u03b2-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and \u03b2-lactam chemistry. Lancet Infect Dis. 2024;24(3):e179\u201388. https:\/\/doi.org\/10.1016\/s1473-3099(23)00432-2.","journal-title":"Lancet Infect Dis"},{"key":"1353_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12050928","author":"V Gostev","year":"2023","unstructured":"Gostev V, Kalinogorskaya O, Sopova J, et al. Adaptive laboratory evolution of Staphylococcus aureus resistance to vancomycin and daptomycin: mutation patterns and cross-resistance. Antibiotics (Basel). 2023. https:\/\/doi.org\/10.3390\/antibiotics12050928.","journal-title":"Antibiotics (Basel)."},{"issue":"11 Pt B","key":"1353_CR9","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/j.bbamem.2015.02.009","volume":"1848","author":"HS Joo","year":"2015","unstructured":"Joo HS, Otto M. Mechanisms of resistance to antimicrobial peptides in Staphylococci. Biochim Biophys Acta. 2015;1848(11 Pt B):3055\u201361. https:\/\/doi.org\/10.1016\/j.bbamem.2015.02.009.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/595738","volume":"199","author":"YQ Xiong","year":"2009","unstructured":"Xiong YQ, Fowler VG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, Bayer AS. Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis. 2009;199(2):201\u20138. https:\/\/doi.org\/10.1086\/595738.","journal-title":"J Infect Dis"},{"key":"1353_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8020071","author":"L Li","year":"2019","unstructured":"Li L, Yeaman MR, Bayer AS, Xiong YQ. Phenotypic and genotypic characteristics of methicillin-resistant Staphylococcus aureus (MRSA) related to persistent endovascular infection. Antibiotics (Basel). 2019. https:\/\/doi.org\/10.3390\/antibiotics8020071.","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"1353_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00109-013-1100-7","volume":"92","author":"G Sakoulas","year":"2014","unstructured":"Sakoulas G, Okumura CY, Thienphrapa W, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl). 2014;92(2):139\u201349. https:\/\/doi.org\/10.1007\/s00109-013-1100-7.","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cir340","volume":"53","author":"A Dhand","year":"2011","unstructured":"Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53(2):158\u201363. https:\/\/doi.org\/10.1093\/cid\/cir340.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1353_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1128\/CMR.00120-16","volume":"30","author":"E Hodille","year":"2017","unstructured":"Hodille E, Rose W, Diep BA, Goutelle S, Lina G, Dumitrescu O. The role of antibiotics in modulating virulence in Staphylococcus aureus. Clin Microbiol Rev. 2017;30(4):887\u2013917. https:\/\/doi.org\/10.1128\/CMR.00120-16.","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"1353_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007446","volume":"4","author":"RR Craven","year":"2009","unstructured":"Craven RR, Gao X, Allen IC, et al. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS ONE. 2009;4(10):e7446. https:\/\/doi.org\/10.1371\/journal.pone.0007446.","journal-title":"PLoS ONE"},{"issue":"5","key":"1353_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.chom.2015.10.011","volume":"18","author":"S Muller","year":"2015","unstructured":"Muller S, Wolf AJ, Iliev ID, Berg BL, Underhill DM, Liu GY. Poorly cross-linked peptidoglycan in MRSA due to mecA induction activates the inflammasome and exacerbates immunopathology. Cell Host Microbe. 2015;18(5):604\u201312. https:\/\/doi.org\/10.1016\/j.chom.2015.10.011.","journal-title":"Cell Host Microbe"},{"key":"1353_CR17","unstructured":"AbbVie. Teflaro (ceftaroline fosamil). Full prescribing information. North Chicago, IL: 2024."},{"key":"1353_CR18","unstructured":"Basilea Pharmaceutica International. Zevtera (ceftobiprole medocaril sodium). Full Prescribing Information. Allschwil, Switzerland: 2024."},{"key":"1353_CR19","doi-asserted-by":"publisher","unstructured":"Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis. 2017;4(2):ofx084. https:\/\/doi.org\/10.1093\/ofid\/ofx084.","DOI":"10.1093\/ofid\/ofx084"},{"issue":"5","key":"1353_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/jcpt.12743","volume":"43","author":"PO Lewis","year":"2018","unstructured":"Lewis PO, Heil EL, Covert KL, Cluck DB. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2018;43(5):614\u201325. https:\/\/doi.org\/10.1111\/jcpt.12743.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"1353_CR21","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1093\/jac\/dkw333","volume":"71","author":"M Dryden","year":"2016","unstructured":"Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. J Antimicrob Chemother. 2016;71(12):3575\u201384. https:\/\/doi.org\/10.1093\/jac\/dkw333.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1353_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dky439","volume":"74","author":"S Das","year":"2019","unstructured":"Das S, Li J, Iaconis J, et al. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. J Antimicrob Chemother. 2019;74(2):425\u201331. https:\/\/doi.org\/10.1093\/jac\/dky439.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1353_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40262-023-01325-4","volume":"63","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Wicha SG, Matzneller P, Kloft C, Zeitlinger M. Impact of key components of intensified ceftaroline dosing on pharmacokinetic\/pharmacodynamic target attainment. Clin Pharmacokinet. 2024;63(1):121\u201331. https:\/\/doi.org\/10.1007\/s40262-023-01325-4.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1353_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/jac\/dky519","volume":"74","author":"K Cheng","year":"2019","unstructured":"Cheng K, Pypstra R, Yan JL, Hammond J. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. J Antimicrob Chemother. 2019;74(4):1086\u201391. https:\/\/doi.org\/10.1093\/jac\/dky519.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1353_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/AAC.01586-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(1):66\u201373. https:\/\/doi.org\/10.1128\/AAC.01586-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1353_CR26","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1128\/AAC.02354-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Vidaillac C, Murray KP, et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013;57(5):2376\u20139. https:\/\/doi.org\/10.1128\/AAC.02354-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1353_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/jac\/dku378","volume":"70","author":"KE Barber","year":"2015","unstructured":"Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother. 2015;70(2):505\u20139. https:\/\/doi.org\/10.1093\/jac\/dku378.","journal-title":"J Antimicrob Chemother"},{"key":"1353_CR28","doi-asserted-by":"publisher","DOI":"10.4137\/cmrt.S1637","author":"C Duplessis","year":"2011","unstructured":"Duplessis C, Crum-Cianflone NF. Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther. 2011. https:\/\/doi.org\/10.4137\/cmrt.S1637.","journal-title":"Clin Med Rev Ther."},{"key":"1353_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","volume":"57","author":"S Arshad","year":"2017","unstructured":"Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017;57:27\u201331. https:\/\/doi.org\/10.1016\/j.ijid.2017.01.019.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"1353_CR30","doi-asserted-by":"publisher","first-page":"ofab606","DOI":"10.1093\/ofid\/ofab606","volume":"9","author":"EJ Zasowski","year":"2022","unstructured":"Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis. 2022;9(3):ofab606. https:\/\/doi.org\/10.1093\/ofid\/ofab606.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1353_CR31","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/jac\/dkaf009","volume":"80","author":"R Bitterman","year":"2025","unstructured":"Bitterman R, Awwad A, Darawsha B, et al. Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study. J Antimicrob Chemother. 2025;80(3):848\u201356. https:\/\/doi.org\/10.1093\/jac\/dkaf009.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1353_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s15010-019-01304-7","volume":"47","author":"T Bhowmick","year":"2019","unstructured":"Bhowmick T, Liu C, Imp B, Sharma R, Boruchoff SE. Ceftaroline as salvage therapy for complicated MRSA bacteremia: case series and analysis. Infection. 2019;47(4):629\u201335. https:\/\/doi.org\/10.1007\/s15010-019-01304-7.","journal-title":"Infection"},{"key":"1353_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02483-18","author":"M Geriak","year":"2019","unstructured":"Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.02483-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1353_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11081104","author":"C Huang","year":"2022","unstructured":"Huang C, Chen I, Lin L. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus vancomycin or daptomycin monotherapy in adults with methicillin-resistant Staphylococcus aureus bacteremia\u2013a meta-analysis. Antibiotics (Basel). 2022. https:\/\/doi.org\/10.3390\/antibiotics11081104.","journal-title":"Antibiotics (Basel)."},{"issue":"2","key":"1353_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40801-024-00422-5","volume":"11","author":"J Hammond","year":"2024","unstructured":"Hammond J, Benigno M, Bleibdrey N, Ansari W, Nguyen JL. Ceftaroline fosamil for the treatment of methicillin-resistant Staphylococcus aureus bacteremia: a real-world comparative clinical outcomes study. Drugs Real World Outcomes. 2024;11(2):273\u201383. https:\/\/doi.org\/10.1007\/s40801-024-00422-5.","journal-title":"Drugs Real World Outcomes"},{"key":"1353_CR36","doi-asserted-by":"publisher","first-page":"204993611988650","DOI":"10.1177\/2049936119886504","volume":"6","author":"JP Hornak","year":"2019","unstructured":"Hornak JP, Anjum S, Reynoso D. Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure. Ther Adv Infect Dis. 2019;6:2049936119886504. https:\/\/doi.org\/10.1177\/2049936119886504.","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"1353_CR37","doi-asserted-by":"publisher","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","volume":"7","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Kullar R, Geriak M, et al. Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2020;7(1):ofz538. https:\/\/doi.org\/10.1093\/ofid\/ofz538.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"1353_CR38","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s10096-020-03941-5","volume":"39","author":"T Morrisette","year":"2020","unstructured":"Morrisette T, Lagnf AM, Alosaimy S, Rybak MJ. A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. Eur J Clin Microbiol Infect Dis. 2020;39(11):2199\u2013203. https:\/\/doi.org\/10.1007\/s10096-020-03941-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"1353_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106310","volume":"57","author":"TM Johnson","year":"2021","unstructured":"Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021;57(4):106310. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106310.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1353_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/phar.2741","volume":"43","author":"WD Kufel","year":"2023","unstructured":"Kufel WD, Parsels KA, Blaine BE, et al. Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy. 2023;43(1):15\u201323. https:\/\/doi.org\/10.1002\/phar.2741.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1353_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106735","volume":"61","author":"D Patel","year":"2023","unstructured":"Patel D, Brown ML, Edwards S, Oster RA, Stripling J. Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Int J Antimicrob Agents. 2023;61(3):106735. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106735.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1353_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/87551225241227796","volume":"40","author":"MG Cabanilla","year":"2024","unstructured":"Cabanilla MG, Bernauer ML, Briski MJ, et al. A retrospective cohort study comparing dual therapy with ceftaroline with vancomycin or daptomycin monotherapy for high-grade or persistent MRSA bacteremia. J Pharm Technol. 2024;40(3):134\u201341. https:\/\/doi.org\/10.1177\/87551225241227796.","journal-title":"J Pharm Technol"},{"issue":"1","key":"1353_CR43","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1186\/s12879-024-10107-7","volume":"24","author":"R Waked","year":"2024","unstructured":"Waked R, Coats L, Rosato A, et al. Clinical outcome of combination of vancomycin and ceftaroline versus vancomycin monotherapy for treatment of methicillin resistant Staphylococcus aureus bloodstream infection. BMC Infect Dis. 2024;24(1):1212. https:\/\/doi.org\/10.1186\/s12879-024-10107-7.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1353_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clinthera.2016.12.005","volume":"39","author":"D Gritsenko","year":"2017","unstructured":"Gritsenko D, Fedorenko M, Ruhe JJ, Altshuler J. Combination therapy with vancomycin and ceftaroline for refractory methicillin-resistant Staphylococcus aureus bacteremia: a case series. Clin Ther. 2017;39(1):212\u20138. https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.005.","journal-title":"Clin Ther"},{"issue":"7","key":"1353_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/1120009x.2024.2340877","volume":"36","author":"YS Alsowaida","year":"2024","unstructured":"Alsowaida YS, Alsolami A, Almangour TA. Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review. J Chemother. 2024;36(7):540\u20135. https:\/\/doi.org\/10.1080\/1120009x.2024.2340877.","journal-title":"J Chemother"},{"issue":"1","key":"1353_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12941-025-00773-z","volume":"24","author":"AS Hicks","year":"2025","unstructured":"Hicks AS, Dolan MA, Shah MD, et al. Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia. Ann Clin Microbiol Antimicrob. 2025;24(1):3. https:\/\/doi.org\/10.1186\/s12941-025-00773-z.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1353_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02015-16","author":"EJ Zasowski","year":"2017","unstructured":"Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/aac.02015-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1353_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/21548331.2019.1676540","volume":"47","author":"ML Mootz","year":"2019","unstructured":"Mootz ML, Britt RS, Mootz AA, et al. Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hosp Pract (1995). 2019;47(4):186\u201391. https:\/\/doi.org\/10.1080\/21548331.2019.1676540.","journal-title":"Hosp Pract (1995)"},{"issue":"12","key":"1353_CR49","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s40121-024-01068-0","volume":"13","author":"KE Caniff","year":"2024","unstructured":"Caniff KE, Judd C, Lucas K, et al. Heartfelt impact: a descriptive analysis of ceftaroline-containing regimens in endocarditis due to methicillin-resistant Staphylococcus aureus. Infect Dis Ther. 2024;13(12):2649\u201362. https:\/\/doi.org\/10.1007\/s40121-024-01068-0.","journal-title":"Infect Dis Ther"},{"key":"1353_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.11.022","author":"S De La Villa","year":"2024","unstructured":"De La Villa S, Escrihuela-Vidal F, Fern\u00e1ndez-Hidalgo N, et al. Ceftaroline for bloodstream infections caused by methicillin-resistant Staphylococcus aureus: a multicentre retrospective cohort study. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.11.022.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"1353_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/ipc.0000000000001284","volume":"31","author":"R El-Lababidi","year":"2023","unstructured":"El-Lababidi R, Abdelsalam M, Hassan A, El Nekidy WS, Alatoom A, Nusair AR. Clinical outcomes of ceftaroline fosamil in the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia: a case series. Infect Dis Clin Pract. 2023;31(5):e1284. https:\/\/doi.org\/10.1097\/ipc.0000000000001284.","journal-title":"Infect Dis Clin Pract"},{"issue":"7","key":"1353_CR52","doi-asserted-by":"publisher","first-page":"ofab327","DOI":"10.1093\/ofid\/ofab327","volume":"8","author":"CN Nichols","year":"2021","unstructured":"Nichols CN, Wardlow LC, Coe KE, Sobhanie MME. Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus bacteremia with retained daptomycin and ceftaroline combination therapy vs de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline. Open Forum Infect Dis. 2021;8(7):ofab327. https:\/\/doi.org\/10.1093\/ofid\/ofab327.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1353_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40121-019-00277-2","volume":"9","author":"O Ahmad","year":"2020","unstructured":"Ahmad O, Crawford TN, Myint T. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline. Infect Dis Ther. 2020;9(1):77\u201387. https:\/\/doi.org\/10.1007\/s40121-019-00277-2.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"1353_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304103","volume":"19","author":"MG Cabanilla","year":"2024","unstructured":"Cabanilla MG, Bernauer ML, Atallah LM, et al. Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: a retrospective single-center study. PLoS ONE. 2024;19(5):e0304103. https:\/\/doi.org\/10.1371\/journal.pone.0304103.","journal-title":"PLoS ONE"},{"key":"1353_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01347-19","author":"G Sakoulas","year":"2019","unstructured":"Sakoulas G, Geriak M, Haddad F, et al. Reply to Kalil et al., \u201cIs daptomycin plus ceftaroline associated with better clinical outcomes than standard of care monotherapy for Staphylococcus aureus bacteremia?\u201d. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.01347-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1353_CR56","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/ciae080","volume":"79","author":"G Sakoulas","year":"2024","unstructured":"Sakoulas G, Tsou EE, Geriak M, Vasina L. Contemporary management of Staphylococcus aureus bacteremia: some additional considerations for clinicians. Clin Infect Dis. 2024;79(3):800\u20131. https:\/\/doi.org\/10.1093\/cid\/ciae080.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1353_CR57","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","volume":"323","author":"SYC Tong","year":"2020","unstructured":"Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527\u201337. https:\/\/doi.org\/10.1001\/jama.2020.0103.","journal-title":"JAMA"},{"key":"1353_CR58","unstructured":"Mylan Institutional LLC. Vancomycin Hydrochloride for Injection (Vancomycin HCl). Full Prescribing Information. Rockford, IL, USA: Mylan Institutional LLC.; 2018."},{"key":"1353_CR59","unstructured":"Sagent Pharmaceuticals. Daptomycin for injection Full Prescribing Information. Schaumburg, IL, USA: Sagent Pharmaceuticals; 2020."},{"issue":"5","key":"1353_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.7861\/clinmedicine.13-5-511","volume":"13","author":"TW Lavender","year":"2013","unstructured":"Lavender TW, McCarron B. Acute infections in intravenous drug users. Clin Med (Lond). 2013;13(5):511\u20133. https:\/\/doi.org\/10.7861\/clinmedicine.13-5-511.","journal-title":"Clin Med (Lond)"},{"issue":"20","key":"1353_CR61","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2022.03.349","volume":"79","author":"E Yucel","year":"2022","unstructured":"Yucel E, Bearnot B, Paras ML, et al. Diagnosis and management of infective endocarditis in people who inject drugs: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(20):2037\u201357. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.349.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1353_CR62","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.12974","volume":"3","author":"C Tan","year":"2020","unstructured":"Tan C, Shojaei E, Wiener J, Shah M, Koivu S, Silverman M. Risk of new bloodstream infections and mortality among people who inject drugs with infective endocarditis. JAMA Netw Open. 2020;3(8):e2012974. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.12974.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1353_CR63","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1060028017735629","volume":"52","author":"JW Jansen","year":"2018","unstructured":"Jansen JW, Moenster RP. Rate and incidence of adverse reactions associated with ceftaroline exposure: importance of cutaneous manifestations. Ann Pharmacother. 2018;52(3):235\u20139. https:\/\/doi.org\/10.1177\/1060028017735629.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1353_CR64","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/jac\/dkx452","volume":"73","author":"RB Turner","year":"2018","unstructured":"Turner RB, Wilson DE, Saedi-Kwon H, et al. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline. J Antimicrob Chemother. 2018;73(3):772\u20138. https:\/\/doi.org\/10.1093\/jac\/dkx452.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1353_CR65","doi-asserted-by":"publisher","first-page":"ofz168","DOI":"10.1093\/ofid\/ofz168","volume":"6","author":"EL Sullivan","year":"2019","unstructured":"Sullivan EL, Turner RB, O\u2019Neal HR Jr, Crum-Cianflone NF. Ceftaroline-associated neutropenia: case series and literature review of incidence, risk factors, and outcomes. Open Forum Infect Dis. 2019;6(5):ofz168. https:\/\/doi.org\/10.1093\/ofid\/ofz168.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1353_CR66","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jac\/dks006","volume":"67","author":"TT Ho","year":"2012","unstructured":"Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267\u201370. https:\/\/doi.org\/10.1093\/jac\/dks006.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1353_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","volume":"19","author":"JC Lin","year":"2013","unstructured":"Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19(1):42\u20139. https:\/\/doi.org\/10.1007\/s10156-012-0449-9.","journal-title":"J Infect Chemother"},{"issue":"2","key":"1353_CR68","doi-asserted-by":"publisher","first-page":"046","DOI":"10.1093\/ofid\/ofu046","volume":"1","author":"V Fabre","year":"2014","unstructured":"Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014;1(2):046. https:\/\/doi.org\/10.1093\/ofid\/ofu046.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1353_CR69","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","volume":"42","author":"HM Polenakovik","year":"2013","unstructured":"Polenakovik HM, Pleiman CM. Ceftaroline for methicillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42(5):450\u20135. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.07.005.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01353-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01353-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01353-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:33:09Z","timestamp":1781803989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01353-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01353-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reece A. Cosimi and Kelsey Pe\u00f1a have nothing to disclose. George Sakoulas is a consultant for AbbVie and Paratek; Speaking for AbbVie, Paratek, Shionogi, Nestle, Innoviva.John L. Lock, Todd Riccobene and Bhavik Nana are employees of AbbVie and may hold stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}